CMS Open Payments · Tool
Seres Therapeutics, Inc. vs ANI Pharmaceuticals, Inc.
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
Seres Therapeutics, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 3,375, versus 98 for the other company. Its single largest recorded recipient represents 0.4% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- Seres Therapeutics, Inc.
- HHI 3,375 · top recipient 0.4%
- Ranked #520 of 1,838 companies by HHI
- ANI Pharmaceuticals, Inc.
- HHI 98 · top recipient 0.1%
- Ranked #1,693 of 1,838 companies by HHI
Payment Overview
Seres Therapeutics, Inc.
- Total Payments
- $1.5M
- % of Industry
- 0.0%
- Transactions
- 198
- Avg per Transaction
- $7.4K
- Recipients
- 42
- Avg per Recipient
- $34.7K
- Payment Types
- 3
- Top Payment Type
- Consulting Fee
ANI Pharmaceuticals, Inc.
- Total Payments
- $1.5M
- % of Industry
- 0.0%
- Transactions
- 21,112
- Avg per Transaction
- $68.96
- Recipients
- 21,104
- Avg per Recipient
- $68.99
- Payment Types
- 5
- Top Payment Type
- Food and Beverage
Highlighted values indicate the higher figure for each metric.
Total payments compared
Seres Therapeutics, Inc. vs ANI Pharmaceuticals, Inc. - total reported payments in CMS Open Payments PY2024
Payment Types Breakdown
Seres Therapeutics, Inc.
8.3%
0.7%
0.0%
ANI Pharmaceuticals, Inc.
38.2%
30.0%
8.1%
1.0%
0.0%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
Seres Therapeutics, Inc.
- 1
Willard Dere
$57,820.55 · 21 txns
- 2
Dennis Ausiello
$37,500.00 · 3 txns
- 3
Timothy Leach
$34,200.00 · 8 txns
- 4
ELIZABETH GHERA
$1,080.00 · 1 txns
- 5
RANDY TAPLITZ
$800.00 · 2 txns
ANI Pharmaceuticals, Inc.
- 1
SUDHAKAR TUMULURI
$68,997.79 · 110 txns
- 2
DHIMAN BASU
$40,112.74 · 70 txns
- 3
REGINA BERKOVICH
$25,256.95 · 51 txns
- 4
PAYAM SHAKOURI
$24,637.75 · 44 txns
- 5
PETROS EFTHIMIOU
$20,383.25 · 26 txns
Summary Comparison
| Metric | Seres Therapeutics, Inc. | ANI Pharmaceuticals, Inc. |
|---|---|---|
| Total Payments | $1.5M | $1.5M |
| % of Industry Total | 0.0% | 0.0% |
| Transaction Count | 198 | 21,112 |
| Avg per Transaction | $7.4K | $68.96 |
| Recipient Count | 42 | 21,104 |
| Avg per Recipient | $34.7K | $68.99 |
| Payment Type Count | 3 | 5 |
| Top Payment Type | Consulting Fee | Food and Beverage |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.